

Prescription Drug Affordability Fund Fee Assessment and Budget Update

May 19, 2025

Andrew York, Executive Director

Maryland Prescription Drug Affordability Board



MARYLAND

Prescription Drug Affordability Board

Agenda

- Summary of Fiscal Year 2025 (FY25) Fee Assessment
- FY25 Budget Update



Summary of FY25 Fee Assessment Policies

- \$1000 flat annual fee assessment on:
 - Manufacturers that sell or offer for sale prescription drug products to persons in the State;
 - Pharmacy benefits managers, as defined in § 15–1601 of the Insurance Article;
 - Carriers, as defined in § 19–132 of this article; and,
 - Wholesale distributors, as defined in § 12–6C–01 of the Health Occupations Article, that sell or offer for sale prescription drug products to persons in the State
- Exemption process if entity is not subject to the assessment because it is not a qualifying entity under COMAR 14.01.01 and Health General § 21-2C-11(b)(1)



Results of FY25 Fee Assessment

- 1,340 Invoices Sent
 - 1,018 entities have paid, with \$1,018,000 in FY25 revenue
 - Approved Exemptions: 57
 - Denied Exemptions: 41
 - Sending approximately 224 entities to CCU



FY 25 Budget Update

FY25 PDAB Budget: As of March 30, 2025

- Appropriation: \$1,247,411.00
- FY25 Cash Revenue: \$1,054,751.02





MARYLAND

Prescription Drug Affordability Board

support.pdab@maryland.gov

pdab.maryland.gov